Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Sanofi has announced that it will be expanding its immunology capabilities by acquiring US-based Blueprint Medicines ...

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical ...

The latest investor updates on stocks that are trending on Monday.

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint ...

The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation to Sanofi is fair to Blueprint shareholders. Under the terms of the proposed ...

PARIS] Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare ...

PARIS] France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its ...

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...